The Covid-19 vaccine being developed by AstraZeneca and Oxford University has been successful in the first phase of its clinical trials.

The AZD1222 vaccine has generated concrete results from the first clinical trials, involving 1,077 healthy adults aged between 18 and 55. The vaccine is proven to be able to generate antibodies and T-cells for at least 56 days, creating a protective shield for the immune system against the coronavirus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, this doesn’t mean the vaccine will be overall successful, it means it is ready for the second stage. People and overall investors placing their hopes on AstraZeneca and Oxford University have to keep in mind that the AZD1222 vaccine it is not ready yet and it has to go through intense testing before commercial use. This is only an indication that based on the data, the vaccine could be successful.

And this is what investors believe as well, placing their trust in AstraZeneca even more than before.

AstraZeneca share price has been on the rise due to recent news of the Covid-19 vaccine being successful

AstraZeneca’s share price traded on the London Stock Exchange has experienced an almost 10% increase under 6 days. Investors reaction to the successful trial announcement of the AZD1222 vaccine raised AstraZeneca’s price to £9,320 from £8,549, under a six-day period.

AstraZeneca has been one of the top 5 performers in FTSE 100, demonstrating the levels of trust investors have placed on the pharmaceutical giant to deliver a Covid-19 vaccine. AstraZeneca’s share price has been on the rise since last April, reflecting early news of the company being on the right course of producing a successful coronavirus vaccine, and how investors react to that news, by buying even more company shares.

However, investors reacting only to news could raise long-term issues if the AZD1222 vaccine turns out to be unsuccessful.

AstraZeneca’s future is placed on the AZD1222 vaccine

As long as the AZD1222 vaccine is successful at the final stage and the use of the vaccine doesn’t have major after effects, then the company will be successful, experiencing the biggest share price increase it has ever.

On the other hand, if the AZD1222 vaccine turns out to be unsuccessful or it would have after-effects placing human life at risk, then it is most certain investors will dump AstraZeneca’s share price by the hundreds.

When a company of that calibre takes a big bet as producing a Covid-19 vaccine, then at the end it could either be very successful or doomed. AstraZeneca seems to be in the right track at the moment, with investors boosting its share price, thus being unsuccessful or not, in the long run, is something that only time and concrete data will tell.